FY2024 EPS Estimates for CG Oncology, Inc. Cut by Analyst (NASDAQ:CGON)

CG Oncology, Inc. (NASDAQ:CGON) – Equities research analysts at Lifesci Capital dropped their FY2024 earnings per share (EPS) estimates for shares of CG Oncology in a research note issued on Tuesday, April 23rd. Lifesci Capital analyst S. Slutsky now anticipates that the company will post earnings per share of ($1.77) for the year, down from their previous estimate of ($1.75). The consensus estimate for CG Oncology’s current full-year earnings is ($1.59) per share. Lifesci Capital also issued estimates for CG Oncology’s FY2025 earnings at ($2.11) EPS and FY2026 earnings at ($1.22) EPS.

Other analysts also recently issued reports about the company. Cantor Fitzgerald began coverage on CG Oncology in a research note on Tuesday, February 20th. They issued an “overweight” rating and a $75.00 price target on the stock. The Goldman Sachs Group began coverage on CG Oncology in a research note on Tuesday, February 20th. They issued a “neutral” rating and a $42.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $75.00 price target on shares of CG Oncology in a research note on Thursday, April 4th. Finally, Morgan Stanley began coverage on CG Oncology in a research note on Tuesday, February 20th. They issued an “overweight” rating and a $55.00 price target on the stock.

CG Oncology Trading Down 0.7 %

Shares of CGON stock opened at $36.05 on Thursday. The company has a 50 day moving average of $40.69. CG Oncology has a twelve month low of $28.55 and a twelve month high of $50.23.

Insider Buying and Selling

In other news, CFO Corleen M. Roche acquired 2,000 shares of CG Oncology stock in a transaction that occurred on Monday, January 29th. The stock was purchased at an average cost of $19.00 per share, with a total value of $38,000.00. Following the completion of the acquisition, the chief financial officer now owns 2,000 shares in the company, valued at approximately $38,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, major shareholder Decheng Capital Global Life Sc acquired 400,000 shares of CG Oncology stock in a transaction that occurred on Monday, January 29th. The stock was purchased at an average cost of $19.00 per share, with a total value of $7,600,000.00. Following the completion of the acquisition, the insider now owns 400,000 shares in the company, valued at approximately $7,600,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Corleen M. Roche acquired 2,000 shares of CG Oncology stock in a transaction that occurred on Monday, January 29th. The shares were purchased at an average cost of $19.00 per share, with a total value of $38,000.00. Following the completion of the acquisition, the chief financial officer now owns 2,000 shares of the company’s stock, valued at approximately $38,000. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 666,472 shares of company stock valued at $12,662,968.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.